Zacks
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
📊
AI Sentiment
Positive
7/10
- Home
- JAZZ
as of 03-18-2026 3:38pm EST
$180.50
$0.88
-0.48%
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 10.4B | IPO Year: | 2007 |
| Target Price: | $215.92 | AVG Volume (30 days): | 944.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.84 | EPS Growth: | -167.51 |
| 52 Week Low/High: | $95.49 - $198.00 | Next Earning Date: | 05-05-2026 |
| Revenue: | $1,618,693,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6.17% | Revenue Growth (next year): | 7.66% |
| P/E Ratio: | -30.96 | Index: | N/A |
| Free Cash Flow: | 1.3B | FCF Growth: | -4.48% |
AI-Powered JAZZ Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.56%
76.56%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
Carr Patricia
Sell
SVP, Chief Accounting Officer
JAZZ Mar 9, 2026
Avg Cost/Share
$182.94
Shares
1,287
Total Value
$235,443.78
Owned After
6,512
SEC Form 4
COZADD BRUCE C
Sell
Director
JAZZ Mar 3, 2026
Avg Cost/Share
$186.89
Shares
6,000
Total Value
$1,118,613.48
Owned After
406,029
RIEDEL NORBERT G
Sell
Director
JAZZ Feb 27, 2026
Avg Cost/Share
$192.00
Shares
3,415
Total Value
$655,680.00
Owned After
7,024
SEC Form 4
Carr Patricia
Sell
SVP, Chief Accounting Officer
JAZZ Feb 27, 2026
Avg Cost/Share
$190.91
Shares
1,117
Total Value
$213,243.45
Owned After
6,512
SEC Form 4
Patil Neena M
Sell
EVP & Chief Legal Officer
JAZZ Feb 26, 2026
Avg Cost/Share
$191.73
Shares
55,600
Total Value
$10,650,482.29
Owned After
56,862
Carr Patricia
Sell
SVP, Chief Accounting Officer
JAZZ Feb 26, 2026
Avg Cost/Share
$194.11
Shares
1,253
Total Value
$243,222.21
Owned After
6,512
SEC Form 4
Henderson Mary Elizabeth
Sell
SVP, Technical Operations
JAZZ Feb 26, 2026
Avg Cost/Share
$194.49
Shares
5,343
Total Value
$1,039,134.42
Owned After
28,728
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 9, 2026 | Sell | $182.94 | 1,287 | $235,443.78 | 6,512 | |
| COZADD BRUCE C | JAZZ | Director | Mar 3, 2026 | Sell | $186.89 | 6,000 | $1,118,613.48 | 406,029 | |
| RIEDEL NORBERT G | JAZZ | Director | Feb 27, 2026 | Sell | $192.00 | 3,415 | $655,680.00 | 7,024 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Feb 27, 2026 | Sell | $190.91 | 1,117 | $213,243.45 | 6,512 | |
| Patil Neena M | JAZZ | EVP & Chief Legal Officer | Feb 26, 2026 | Sell | $191.73 | 55,600 | $10,650,482.29 | 56,862 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Feb 26, 2026 | Sell | $194.11 | 1,253 | $243,222.21 | 6,512 | |
| Henderson Mary Elizabeth | JAZZ | SVP, Technical Operations | Feb 26, 2026 | Sell | $194.49 | 5,343 | $1,039,134.42 | 28,728 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
AI Prediction SELL
1D
+0.07%
$173.95
Act: +13.23%
5D
-1.16%
$171.81
Act: +7.39%
20D
+5.40%
$183.21
Price: $173.83 Prob +5D: 0% AUC: 1.000
0001232524-26-000012
jazz-202602240001232524falseJazz Pharmaceuticals plc00012325242026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 24, 2026 Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland 001-33500 98-1032470 (State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7 (Address of principal executive offices, including zip code)
011-353-1-634-7800 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
JAZZ
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 24, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the full year and fourth quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this current report. The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
Exhibit NumberDescription
99.1Press Release dated February 24, 2026.
104104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
By:/s/ Philip L. Johnson Name:Philip L. Johnson Title:Executive Vice President and Chief Financial Officer
Date: February 24, 2026
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
+0.07%
$173.95
Act: +13.23%
5D
-1.16%
$171.81
Act: +7.39%
20D
+5.40%
$183.21
Price: $173.83 Prob +5D: 0% AUC: 1.000
0001193125-26-009899
8-K
Jazz Pharmaceuticals plc false 0001232524 0001232524 2026-01-12 2026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland
001-33500
98-1032470
(State or Other Jurisdiction of Incorporation)
(Commission File No.)
(IRS Employer Identification No.)
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7 (Address of principal executive offices, including zip code) 011-353-1-634-7800 (Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
JAZZ
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 13, 2026, Jazz Pharmaceuticals plc (the “Company”) will present a corporate overview and financial update at the J.P. Morgan Healthcare Conference in San Francisco, California, which presentation includes (i) the Company’s expectations that it will meet its previously announced total revenue guidance range for the year ended December 31, 2025 and (ii) the Company’s expectations with respect to the revenue for each of Xywav, Epidiolex and Modeyso for the year ended December 31, 2025. A copy of the presentation is attached hereto as Exhibit 99.1. The information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 of this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Presentation slides by Jazz Pharmaceuticals plc on January 13, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
By:
/s/ Philip L. Johnson
Name:
Philip L. Johnson
Title:
Executive Vice President and Chief Financial Officer
Date: January 12, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001232524-25-000073
jazz-202511050001232524falseJazz Pharmaceuticals plc00012325242025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 5, 2025 Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland 001-33500 98-1032470 (State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7 (Address of principal executive offices, including zip code)
011-353-1-634-7800 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
JAZZ
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 5, 2025, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this current report. The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
Exhibit NumberDescription
99.1Press Release dated November 5, 2025.
104104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
By:/s/ Philip L. Johnson Name:Philip L. Johnson Title:Executive Vice President and Chief Financial Officer
Date: November 5, 2025
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
Compare JAZZ vs Leading Stocks
See how JAZZ stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.